Agreed. The only thing from a laypersons perspective that might be an issue is that one of the key side effects was a potential for bruising (body wide, not just at the injection site), indicating a possible effect on capillary strength or stability. Not sure if it had a more general effect on the vascular system. Considering that the assumed cohort for this medication would generally be elderly, how many would be on blood thinners such as Warfarin? Not a biggie, but just something else for the developers to consider.
Enlighten me please., page-14
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.5¢ | 21.5¢ | $328.0K | 1.416M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 19775 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |